Mpox Cases Double in 2024

According to the recent Nationally Notifiable Infectious Diseases and Conditions weekly report, the number of mpox cases in the United States has more than doubled compared to Week #15 in 2023.

As of April 13, 2024, 750 mpox cases had been reported, compared to 336 cases at the same time last year.

The U.S. CDC highlights New York City (151), California (72), and Texas (55) as mpox case leaders.

The U.S. Health and Human Services (HHS) was initially charged with coordinating the federal response to the mpox outbreak. According to the General Accountability report issued on April 18, 2024, HHS is recommended to adopt a coordinated, department-wide program that incorporates input from external stakeholders to identify and resolve challenges.

In the United States, Bavarian Nordic's JYNNEOS® vaccine was initially offered to healthcare staff in Boston on May 24, 2022.

Since then, over 1.2 million (1-dose: 38.8% and 2-dose: 24.3%) JYNNEOS doses have been administered in U.S. Jurisdictions. 

As of April 2024, JYNNEOS remains the only FDA-approved non-replicating smallpox and mpox vaccine for military and non-military use and has recently become commercially available at U.S. pharmacies.